Precision Medication: An Illustrative Case Series Guiding the Clinical Application of Multi-drug Interactions and Pharmacogenomics

Overview

Journal Clin Case Rep

Date 2020 Mar 5

PMID 32128178

Citations 4

Authors

Kevin T Bain

David McGain

Emily J Cicali

Calvin H Knowlton

Veronique Michaud

Jacques Turgeon

Affiliations

Soon will be listed here.

Abstract

Precision medication entails selecting the precise medication, dose, and timing of administration. Multi-drug interactions and genetics significantly affect precision medication. In this article, we present two simulated cases for real-world applications of precision medication. Clinicians may need to acquire additional skills to apply the principles illustrated by these cases.

Citing Articles

Evaluating the Impact of Medication Risk Mitigation Services in Medically Complex Older Adults.

Jin H, Yang S, Bankes D, Finnel S, Turgeon J, Stein A Healthcare (Basel). 2022; 10(3).

PMID: 35327028 PMC: 8950840. DOI: 10.3390/healthcare10030551.

Effectiveness of an Advanced Clinical Decision Support System on Clinical Decision-Making Skills in a Call Center Medication Therapy Management Pharmacy Setting: A Pilot Study.

Bingham J, Michaud V, Turgeon J, Axon D Pharmacy (Basel). 2020; 8(4).

PMID: 33255726 PMC: 7712249. DOI: 10.3390/pharmacy8040228.

Opioids, Polypharmacy, and Drug Interactions: A Technological Paradigm Shift Is Needed to Ameliorate the Ongoing Opioid Epidemic.

Matos A, Bankes D, Bain K, Ballinghoff T, Turgeon J Pharmacy (Basel). 2020; 8(3).

PMID: 32854271 PMC: 7559875. DOI: 10.3390/pharmacy8030154.

Precision medication: An illustrative case series guiding the clinical application of multi-drug interactions and pharmacogenomics.

Bain K, McGain D, Cicali E, Knowlton C, Michaud V, Turgeon J Clin Case Rep. 2020; 8(2):305-312.

PMID: 32128178 PMC: 7044418. DOI: 10.1002/ccr3.2604.

References

Zakrzewski-Jakubiak H, Doan J, Lamoureux P, Singh D, Turgeon J, Tannenbaum C . Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software. Am J Geriatr Pharmacother. 2011; 9(6):461-70. DOI: 10.1016/j.amjopharm.2011.09.006. View

Hulot J, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C . Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108(7):2244-7. DOI: 10.1182/blood-2006-04-013052. View

Simon N, Finzi J, Cayla G, Montalescot G, Collet J, Hulot J . Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol. 2015; 71(9):1059-66. DOI: 10.1007/s00228-015-1882-3. View

Shah R, Smith R . Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol. 2014; 79(2):222-40. PMC: 4309629. DOI: 10.1111/bcp.12441. View

Roman M, Ochoa D, Sanchez-Rojas S, Talegon M, Prieto-Perez R, Rivas A . Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. Pharmacogenomics. 2014; 15(15):1893-901. DOI: 10.2217/pgs.14.141. View

Ferri N, Corsini A, Bellosta S . Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013; 73(15):1681-709. DOI: 10.1007/s40265-013-0126-z. View

Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A . Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study. Eur Heart J. 2003; 24(19):1744-9. DOI: 10.1016/s0195-668x(03)00442-1. View

Boulenc X, Djebli N, Shi J, Perrin L, Brian W, Van Horn R . Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite. Drug Metab Dispos. 2011; 40(1):187-97. DOI: 10.1124/dmd.111.040394. View

Verbeurgt P, Mamiya T, Oesterheld J . How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 2014; 15(5):655-65. DOI: 10.2217/pgs.14.6. View

10.

Lau W, Waskell L, Watkins P, Neer C, Horowitz K, Hopp A . Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003; 107(1):32-7. DOI: 10.1161/01.cir.0000047060.60595.cc. View

11.

Mackenzie I, Coughtrie M, MacDonald T, Wei L . Antiplatelet drug interactions. J Intern Med. 2010; 268(6):516-29. DOI: 10.1111/j.1365-2796.2010.02299.x. View

12.

Bain K, McGain D, Cicali E, Knowlton C, Michaud V, Turgeon J . Precision medication: An illustrative case series guiding the clinical application of multi-drug interactions and pharmacogenomics. Clin Case Rep. 2020; 8(2):305-312. PMC: 7044418. DOI: 10.1002/ccr3.2604. View

13.

Preskorn S, Kane C, Lobello K, Nichols A, Fayyad R, Buckley G . Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry. 2013; 74(6):614-21. DOI: 10.4088/JCP.12m07807. View

14.

Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D . Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94(3):317-23. PMC: 3748366. DOI: 10.1038/clpt.2013.105. View

15.

Angiolillo D, Gibson C, Cheng S, Ollier C, Nicolas O, Bergougnan L . Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2010; 89(1):65-74. DOI: 10.1038/clpt.2010.219. View

16.

Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L . Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009; 54(13):1149-53. DOI: 10.1016/j.jacc.2009.05.050. View

17.

Fernando H, Bassler N, Habersberger J, Sheffield L, Sharma R, Dart A . Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost. 2011; 9(8):1582-9. DOI: 10.1111/j.1538-7836.2011.04414.x. View

18.

Norgard N, Mathews K, Wall G . Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009; 43(7):1266-74. DOI: 10.1345/aph.1M051. View

19.

Michaud V, Vanier M, Brouillette D, Roy D, Verret L, Noel N . Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin Pharmacol Ther. 2007; 83(5):740-8. DOI: 10.1038/sj.clpt.6100434. View

20.

Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C . Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013; 47(3):324-32. DOI: 10.1345/aph.1R621. View